Up to 20% of patients with COVID-19 have associated skin changes, including maculopapular, vesicular and vaso-occlusive rashes, urticaria and ‘COVID toes’. Some of these are markers of disease progression and severity.

The effective management of atopic dermatitis requires a solid foundation of education around general measures, coupled with stepwise pharmacological treatments and follow up. Two additional systemic treatment options have recently been approved for patients who have inadequately responded to first-line treatment.

Many viral rashes can be diagnosed clinically, based on knowledge of their epidemiology and typical morphology and distribution.

Pigmented skin is protected against UV damage and the development of certain skin cancers. However, some skin conditions are more prevalent in darker skinned communities. GPs should be aware that such patients are still at risk of developing skin cancer and early diagnosis and considered management are key to improving patient outcomes.

What are these painful lesions and how should this patient be managed?